[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-2-dm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-2-dm":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,66,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100585766","implementation-program-to-improve-screening-and-management-for-ckd-in-diabetes-iris-ckd-program-2-100585766",false,"NCT06906640","Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)","Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 2) (IRIS-CKD)","IRIS-CKD","Inclusion Criteria:\n\n* (CKD Management)\n\n  * Adults with type 2 diabetes (T2D)\n  * Receiving primary care within the healthcare system, visit within 24 months (any PCP provider, including APP)\n  * Evidence of CKD based on laboratory testing within the past 2 years (must be confirmed during screening if not checked within 3 months of enrollment):\n\n    * UACR \\>300 mg\u002Fg or\n    * eGFR \\\u003C45 ml\u002Fmin\u002F1.73 m2 or\n    * UACR ≥30 mg\u002Fg with eGFR \\\u003C60 ml\u002Fmin\u002F1.73 m2\n  * Receiving \\\u003C100% GDMT at baseline. For patients with UACR \\\u003C30 mg\u002Fg, GDMT includes sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy. For all other eligible patients, GDMT includes ACEi\u002FARB, SGLT2i, and Finerenone, unless contraindications for any of these therapies exist (e.g., hyperkalemia, diabetic ketoacidosis, etc.).\n\nExclusion Criteria:\n\n* (CKD Management)\n\n  * Type 1 diabetes\n  * Most recent eGFR \\\u003C20 ml\u002Fmin\u002F1.73 m2\n  * Prior kidney transplant\n  * Autosomal dominant polycystic kidney disease (ADPKD)\n  * Active pregnancy or plans for conception within 1 year","ALL","18 Years",{"count":20,"type":21},420,"ESTIMATED","INTERVENTIONAL",[24],"NA","IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.",[27,28,29],"Chronic Kidney Disease(CKD)","Type 2 DM","Type 2 Diabetes Mellitus (T2DM)",[31,32,33,34,35],"CKD","T2DM","T2D","Type 2 Diabetes","Chronic kidney disease","RECRUITING","2026-06-15",{"date":39,"type":40},"2026-06-16","ACTUAL",{"date":42,"type":40},"2025-10-28",{"date":44,"type":21},"2027-04-01",{"name":46,"class":47},"Duke University","OTHER",7,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":15,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":65,"locationsCount":48},"100585765","implementation-program-to-improve-screening-and-management-for-ckd-in-diabetes-program-1-iris-ckd-100585765","NCT06906627","Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)","Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD)","Screening Program-\n\nInclusion Criteria:\n\n* Adults with type 2 diabetes (T2D)\n* Receiving primary care within the healthcare system, Primary Care Provider (PCP) visit within the past 24 months (any PCP provider, including APP).\n* Lack of estimated glomerular filtration rate (eGFR) and\u002For urine albumin- creatinine ratio (UACR) measurement in the prior 15 months within the EHR\n\nExclusion Criteria:\n\n• Chronic kidney disease (CKD) diagnosis",{"count":57,"type":21},750,[24],"IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.",[27,28,29],[31,32,33,34,35],{"date":39,"type":40},{"date":42,"type":40},{"date":44,"type":21},{"name":46,"class":47},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100582394","phase-4-glycemic-control-with-triple-pathway-approach-through-empagliflozin-linagliptin-and-metformin-combination-100582394","NCT06862739","Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination","Glycemic Control With Triple Pathway Approach Through Empagliflozin-Linagliptin-Metformin","GLYCO-3P","Inclusion criteria\n\n1. Patients of any gender\n2. Patients aged between 18-80 years\n3. Patients having HbA1c 8 % or above\n4. Patients diagnosed with type II diabetes (more than at least 06 months)\n5. Patients already on at least 02 or more anti-diabetic agents\n6. Patients not allergic to empagliflozin, linagliptin, or metformin\n\nExclusion criteria\n\n1. Patients with age less than 18\n2. Patients with Type-I diabetes\n3. Patients having diabetes for less than 06 months\n4. Patients on GLP-1 and GIP\n5. Patients who are pregnant or lactating females\n6. Patients with decompensated chronic liver disease (DCLD)\n7. Patients with eGFR less than 30 ml\n8. Patients with end-stage heart failure (NYHA Class 4)\n9. Patients who are allergic to empagliflozin, linagliptin, or metformin\n10. Patients who are not willing to consent\n11. Patients who are unable to give medical history","80 Years",{"count":76,"type":21},800,[78],"PHASE4","The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.",[81,28],"Diabetes Mellitus",[83,84,85,86,87,88,89,90,91,92,28],"Combination","empagliflozin","metformin","linagliptin","compliance","Hypoglycemic events","weight management","quality of life","treatment satisfaction","glycemic control","2026-04-14",{"date":95,"type":40},"2026-04-17",{"date":97,"type":40},"2025-10-30",{"date":99,"type":21},"2026-06-30",{"name":101,"class":102},"Nabiqasim Industries (Pvt) Ltd","INDUSTRY",2,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100571345","telehealth-based-chronic-disease-management-for-type-2-diabetes-100571345","NCT06719050","Telehealth-Based Chronic Disease Management for Type 2 Diabetes","Application and Evaluation of Telehealth-Based Chronic Disease Management for Type 2 Diabetes","T2DMTH","Inclusion Criteria:\n\n* 18-70 years old;\n* Confirmed diagnosis of type 2 diabetes mellitus;\n* Ability to use smartphones to participate in online diagnosis and treatment;\n* Ability of the patient or relatives to assist the patient in self-monitoring of blood glucose;\n* Failure to meet control targets: glycated hemoglobin ≥7. 0%, or LDL-C ≥ 2.6 mmol\u002FL (and ASCVD or definite atherosclerosis with stenosis ≥ 1.8 mmol\u002FL), or blood pressure \\> 130% and ≥ 1.8 mmol\u002Fkg. L), or blood pressure over 130\u002F80 mmHg.\n\nExclusion Criteria:\n\n* Mental illness, cognitive dysfunction;\n* Other diseases and complex conditions (untreated tumors, heart disease within 3 months);\n* Acute complications of diabetes, severe hyperglycemia, fasting glucose greater than 16.9 mmol \u002F L, random glucose greater than 20 mmol \u002F L. Diabetic ketoacidosis and hypoglycemic coma that are not suitable for online management of diabetes emergencies;\n* Patients with severe chronic complications of diabetes in critical condition (blindness, vision deterioration, new onset of ASCVD symptoms);\n* Those who are unsuitable for the study: infection, fracture, trauma, foot ulceration, edema, blindness, cardiovascular emergencies, coma, etc;\n* Those who have not signed the informed consent form.","70 Years",{"count":114,"type":21},1636,"OBSERVATIONAL","This study will be conducted from enrollment until the end of the six-month follow-up period.\n\nThis study aims to assess the impact of the Internet hospital online + offline integrated chronic disease management model on patients with type 2 diabetes mellitus. It will also evaluate the economic impact of the model and identify the characteristics of the appropriate population for the model. Finally, it will develop a toolkit to help manage chronic diseases.\n\nThe study will include 1,636 patients with type 2 diabetes who did not reach the standard of control target of glucose, blood pressure or LDL at the endocrine outpatient clinic and inpatient wards of the Third Hospital of Peking University. We will collect information from participants before the study starts. And the patients will be followed up for 6 months from enrollment. The study management mode included online and offline integrated management in the Internet hospital, and routine offline management mode. After completing the enrollment and assessment, we will arrange outpatient follow-up and management according to the current status, doctor's requirements, and study subjects' needs.",[28],"NOT_YET_RECRUITING","2024-12-02",{"date":121,"type":40},"2024-12-05",{"date":123,"type":21},"2024-12-18",{"date":125,"type":21},"2027-12-31",{"name":127,"class":47},"Zeng Lin, Ph. D."]